The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Drug-Related Fatality Stops Hepatitis C Trial

Back to News Homepage

Next

Hepatitis C Biopump Trials Get Green Light

Concerns Halt Idenix Hep C Drug

August 31, 2012

Print this page

Because of its likeness to Bristol-Myers’ Hepatitis C drug that was associated with heart problems, Idenix’s IDX19368 has been placed on a clinical hold by the FDA.

Idenix: FDA Places Hepatitis C Treatment on Clinical Hold

Published August 27, 2012

Dow Jones Newswires

Idenix Pharmaceuticals Inc. (IDIX) said the Food and Drug Administration placed a clinical hold on one of its treatments for hepatitis C, the latest setback for the drug developer.

The clinical hold on the treatment–IDX19368–is related to the regulator’s heart-safety concerns about rival Bristol-Myers Squibb Co.’s (BMY) closely watched treatment for the liver disease, which belongs to the same class of drugs–known as nucleotide polymerase inhibitors.

Continue reading this entire article:
http://www.foxbusiness.com/news/2012/08/27/idenix-fda-places-hepatitis-c-treatment-on-clinical-hold/

No Comments - be the first!
Share
Share

Previous

Drug-Related Fatality Stops Hepatitis C Trial

Back to News Homepage

Next

Hepatitis C Biopump Trials Get Green Light

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.